Maze Therapeutics (NASDAQ:MAZE) CMO Sells $436,809.10 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 14,609 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10. Following the sale, the chief marketing officer directly owned 14,609 shares of the company’s stock, valued at approximately $436,809.10. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, May 14th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00.

Maze Therapeutics Price Performance

MAZE stock opened at $31.26 on Friday. Maze Therapeutics, Inc. has a one year low of $10.98 and a one year high of $53.65. The company’s fifty day moving average price is $26.02 and its 200-day moving average price is $35.64. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The company has a market capitalization of $1.73 billion, a PE ratio of -12.36 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. On average, equities analysts anticipate that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Trading of Maze Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada lifted its position in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics in the fourth quarter valued at $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics in the fourth quarter valued at $43,000. California State Teachers Retirement System lifted its holdings in shares of Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after acquiring an additional 766 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on MAZE shares. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Wedbush boosted their target price on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. JPMorgan Chase & Co. raised their price target on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.